Group items tagged

Biotechs were harder hit than most other sectors during the recent volatility as investors fled to blue-chips and other safer stocks. Today the strongest of the sector began to recover as investors saw the lower levels as a...

Not only do companies have the potential to achieve what Novavax was able to under the right circumstances, but the industry is also full of big mergers and acquisitions. Early-stage companies develop clinical trial pipelines. Larger companies may then target these smaller firms as buyout candidates. For instance, Merck (NYSE: MRK) bought cancer drug research company VelosBio Inc. from Pappas Capital and other investors for $2.75 billion. Gilead Sciences (NASDAQ: GILD) picked up Immunomedics for $21 billion to gain access to a breast cancer treatment, Trodelvy. The list goes on. In this article, we'll look at a few current and former biotech penny stocks that have continued demonstrating strength in the stock market in 2021.

Enthusiasm for the bitoech sector has been dwindling as investors avoid doubling up on volatility in the current market but Pfizer's latest rheumatoid arthritis may tempt the pro-risk buyer.

Medical device stocks are somewhat insulated from the volatility of the economy on a long-term basis. A combination of recent weakness has led to attractive valuations.

The late stage studies of Bayer's oncology drug, Alpharadin are impressive to say the least. Designed for the treatment of prostate cancer that spreads to the bones, the drug is able to extend life of late-stage patients while minimizing damage to healthy tissue.

As the first new Lupus drug to debut in the last half-of-a-century, Benlysta has the potential to be something special. Reception of the drug from doctors has been lukewarm thus far, but with many other treatments associated with severe potential side effects, Benlysta may be a blockbuster nonetheless.

These three companies appear to have the potential for major upsides either as a result of an upcoming event or a structural change ahead. There are a lot of bargain buys out there right now but not all are created equal. These three look as though they might be the cream of the crop.

Some of the latest published analysis of Merck indicates a yield of as much as 4.6 percent after three quarters of strong earnings. At its current low-price Merck is gaining appeal.

This article discusses a handful of penny stocks with exposure to potential Alzheimer's disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB) and Eisai Co.'s experimental Alzheimer's drug significantly slowed the progression of the disease in a large study. The 18-month, Phase 3 study of 1,800 patients tested the treatment on early-stage Alzheimer's patients. 4 more Alzheimer's stocks to watch